Squarepoint Ops LLC Sells 28,916 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Squarepoint Ops LLC trimmed its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 34.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,439 shares of the biotechnology company’s stock after selling 28,916 shares during the quarter. Squarepoint Ops LLC owned approximately 0.14% of Oramed Pharmaceuticals worth $132,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ORMP. Boothbay Fund Management LLC lifted its holdings in Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after purchasing an additional 16,857 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 70,190 shares in the last quarter. BML Capital Management LLC lifted its holdings in Oramed Pharmaceuticals by 20.9% during the fourth quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after purchasing an additional 457,716 shares in the last quarter. World Equity Group Inc. purchased a new position in Oramed Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, Peapod Lane Capital LLC purchased a new position in shares of Oramed Pharmaceuticals in the fourth quarter worth $550,000. 12.73% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Stock Up 0.5%

ORMP stock opened at $2.23 on Tuesday. Oramed Pharmaceuticals Inc. has a twelve month low of $1.82 and a twelve month high of $3.09. The stock has a market capitalization of $91.10 million, a price-to-earnings ratio of 20.27 and a beta of 1.63. The firm’s fifty day simple moving average is $2.21 and its two-hundred day simple moving average is $2.29.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.16). The firm had revenue of $2.00 million for the quarter. As a group, equities research analysts expect that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 17th.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.